Novartis Financials
| NVSN Stock | MXN 2,004 134.33 6.28% |
Novartis |
Please note, the imprecision that can be found in Novartis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novartis AG. Check Novartis' Beneish M Score to see the likelihood of Novartis' management manipulating its earnings.
Novartis Stock Summary
Novartis competes with AbbVie, AstraZeneca PLC, and GlaxoSmithKline Plc. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 105794 people.| Instrument | Mexico Stock View All |
| Exchange | Mexican Exchange |
| ISIN | US66987V1098 |
| Business Address | Lichtstrasse 35, Basel, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.novartis.com |
| Phone | 41 61 324 1111 |
| Currency | MXN - Mexican Peso |
You should never invest in Novartis without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Novartis Stock, because this is throwing your money away. Analyzing the key information contained in Novartis' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Novartis Key Financial Ratios
Novartis' financial ratios allow both analysts and investors to convert raw data from Novartis' financial statements into concise, actionable information that can be used to evaluate the performance of Novartis over time and compare it to other companies across industries.| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Beta | 0.47 | |||
| Last Dividend Paid | 3.46 |
Novartis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.Novartis AG is regarded third in return on equity category among its peers. It also is regarded third in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novartis AG is roughly 1.69 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novartis by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novartis' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Novartis AG Systematic Risk
Novartis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novartis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Novartis AG correlated with the market. If Beta is less than 0 Novartis generally moves in the opposite direction as compared to the market. If Novartis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novartis AG is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novartis is generally in the same direction as the market. If Beta > 1 Novartis moves generally in the same direction as, but more than the movement of the benchmark.
Novartis December 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Novartis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novartis AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novartis AG based on widely used predictive technical indicators. In general, we focus on analyzing Novartis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novartis's daily price indicators and compare them against related drivers.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 4.88 | |||
| Value At Risk | (1.09) |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.